{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:06Z","timestamp":1787624346667,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05454-y","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:56:07Z","timestamp":1778644567000},"page":"16915-16928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Denosumab safety in men with osteoporosis: a disproportionality analysis of the FAERS database"],"prefix":"10.1007","volume":"399","author":[{"given":"Hou-hong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-long","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"5454_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","volume":"31","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388\u2013393. https:\/\/doi.org\/10.1097\/BOR.0000000000000608","journal-title":"Curr Opin Rheumatol"},{"key":"5454_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2019.100239","volume":"12","author":"M Al-Attar","year":"2020","unstructured":"Al-Attar M, De Santis M, Massarotti M (2020) DRESS syndrome in response to Denosumab: first documented case report. Bone Rep 12:100239. https:\/\/doi.org\/10.1016\/j.bonr.2019.100239","journal-title":"Bone Rep"},{"key":"5454_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176:182\u2013195. https:\/\/doi.org\/10.7326\/M22-0684","journal-title":"Ann Intern Med"},{"key":"5454_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.20945\/2359-3997000000563","volume":"66","author":"L Bandeira","year":"2022","unstructured":"Bandeira L, Silva BC, Bilezikian JP (2022) Male osteoporosis. Arch Endocrinol Metab 66:739\u2013747. https:\/\/doi.org\/10.20945\/2359-3997000000563","journal-title":"Arch Endocrinol Metab"},{"key":"5454_CR5","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","volume":"27","author":"C Beaudoin","year":"2016","unstructured":"Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835\u20132844. https:\/\/doi.org\/10.1007\/s00198-016-3607-6","journal-title":"Osteoporos Int"},{"key":"5454_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3027419","volume":"2019","author":"RD Bhanot","year":"2019","unstructured":"Bhanot RD, Kaur J, Bhat Z (2019) Severe hypocalcemia and dramatic increase in parathyroid hormone after Denosumab in a dialysis patient: a case report and review of the literature. Case Rep Nephrol 2019:3027419. https:\/\/doi.org\/10.1155\/2019\/3027419","journal-title":"Case Rep Nephrol"},{"key":"5454_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of Denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479. https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"},{"key":"5454_CR8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00198-010-1419-7","volume":"22","author":"SW Blume","year":"2011","unstructured":"Blume SW, Curtis JR (2011) Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int 22:1835\u20131844. https:\/\/doi.org\/10.1007\/s00198-010-1419-7","journal-title":"Osteoporos Int"},{"key":"5454_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","volume":"12","author":"JJ Body","year":"2006","unstructured":"Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221\u20131228. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1933","journal-title":"Clin Cancer Res"},{"key":"5454_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/all.12184","volume":"68","author":"K Eyerich","year":"2013","unstructured":"Eyerich K, Novak N (2013) Immunology of atopic eczema: overcoming the Th1\/Th2 paradigm. Allergy 68:974\u2013982. https:\/\/doi.org\/10.1111\/all.12184","journal-title":"Allergy"},{"key":"5454_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s43441-024-00712-8","volume":"59","author":"S Gao","year":"2025","unstructured":"Gao S, Zheng G, He Z, Chen L, Yan D, Lai Z, Cai T, Hu S (2025) Hypocalcemia event associated with denosumab: a real-world study from FDA Adverse Event Reporting System (FAERS) database. Ther Innov Regul Sci 59:135\u2013141. https:\/\/doi.org\/10.1007\/s43441-024-00712-8","journal-title":"Ther Innov Regul Sci"},{"key":"5454_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E (2021) Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol 28:983\u2013989. https:\/\/doi.org\/10.1177\/2047487320915663","journal-title":"Eur J Prev Cardiol"},{"key":"5454_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14656566.2018.1428559","volume":"19","author":"L Gennari","year":"2018","unstructured":"Gennari L, Bilezikian JP (2018) New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother 19:253\u2013264. https:\/\/doi.org\/10.1080\/14656566.2018.1428559","journal-title":"Expert Opin Pharmacother"},{"key":"5454_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1573353","volume":"16","author":"TA Hammad","year":"2025","unstructured":"Hammad TA, Naylor M, Ely DM, Davies S (2025) Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action. Front Pharmacol 16:1573353. https:\/\/doi.org\/10.3389\/fphar.2025.1573353","journal-title":"Front Pharmacol"},{"key":"5454_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00198-024-07381-1","volume":"36","author":"Z Huang","year":"2025","unstructured":"Huang Z, Liao TC, Chuang AT, Shao SC, Lange J, Lin TC, Kim M, Lai EC (2025) Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. Osteoporos Int 36:465\u2013473. https:\/\/doi.org\/10.1007\/s00198-024-07381-1","journal-title":"Osteoporos Int"},{"key":"5454_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3904\/kjim.2022.064","volume":"37","author":"C Jeong","year":"2022","unstructured":"Jeong C, Ha J, Kim J, Lim Y, Kim MK, Kwon HS, Song KH, Kang MI, Baek KH (2022) The efficacy of denosumab in Korean male patients with osteoporosis. Korean J Intern Med 37:1011\u20131020. https:\/\/doi.org\/10.3904\/kjim.2022.064","journal-title":"Korean J Intern Med"},{"key":"5454_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3803\/EnM.2023.1663","volume":"38","author":"C Jeong","year":"2023","unstructured":"Jeong C, Lee J, Kim J, Ha J, Jo K, Lim Y, Kim MK, Kwon HS, Sohn TS, Song KH, Kang MI, Baek KH (2023) Persistence with denosumab in male osteoporosis patients: a real-world, non-interventional multicenter study. Endocrinol Metab 38:260\u2013268. https:\/\/doi.org\/10.3803\/EnM.2023.1663","journal-title":"Endocrinol Metab"},{"key":"5454_CR18","doi-asserted-by":"publisher","first-page":"e32784","DOI":"10.1097\/MD.0000000000032784","volume":"102","author":"X Jiang","year":"2023","unstructured":"Jiang X, Xie T, Feng W, Qin Z, Liao S, Liu Y, Lu S, He M, Wei Q (2023) Trends of denosumab-related publications in Web of Science. Medicine (Baltimore) 102:e32784. https:\/\/doi.org\/10.1097\/MD.0000000000032784","journal-title":"Medicine (Baltimore)"},{"key":"5454_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"5454_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3803\/EnM.2021.1193","volume":"36","author":"BK Kim","year":"2021","unstructured":"Kim BK, Kim CH, Min YK (2021) Preventing rebound-associated fractures after discontinuation of denosumab therapy: a position statement from the Health Insurance Committee of the Korean Endocrine Society. Endocrinol Metab 36:909\u2013911. https:\/\/doi.org\/10.3803\/EnM.2021.1193","journal-title":"Endocrinol Metab"},{"key":"5454_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62736","volume":"16","author":"J Krishnan","year":"2024","unstructured":"Krishnan J, Santhanam S, Singh B, Patel S, Bhojwani DG, Muchhala S (2024) Denosumab: a useful addition to the armamentarium for the management of male osteoporosis. Cureus 16:e62736. https:\/\/doi.org\/10.7759\/cureus.62736","journal-title":"Cureus"},{"key":"5454_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(05)17831-3","volume":"365","author":"N Lameire","year":"2005","unstructured":"Lameire N, Van Biesen W, Van holder R (2005) Acute renal failure. Lancet 365:417\u2013430. https:\/\/doi.org\/10.1016\/S0140-6736(05)17831-3","journal-title":"Lancet"},{"key":"5454_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbjaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E (2015) A 24-month study evaluating the efficacy and safety of Denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol 100:1335\u20131342. https:\/\/doi.org\/10.1210\/jc.2014-4079","journal-title":"J Clin Endocrinol"},{"key":"5454_CR24","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/nm1518","volume":"12","author":"K Loser","year":"2006","unstructured":"Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372\u20131379. https:\/\/doi.org\/10.1038\/nm1518","journal-title":"Nat Med"},{"key":"5454_CR25","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.4158\/ACCR-2018-0295","volume":"5","author":"RV McCaleb","year":"2019","unstructured":"McCaleb RV, Johnson JT (2019) Severe, prolonged, Denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation. AACE Clin Case Rep 5:e82\u2013e85. https:\/\/doi.org\/10.4158\/ACCR-2018-0295","journal-title":"AACE Clin Case Rep"},{"key":"5454_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40265-012-0003-1","volume":"73","author":"L Mosekilde","year":"2013","unstructured":"Mosekilde L, Vestergaard P, Rejnmark L (2013) The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 73:15\u201329. https:\/\/doi.org\/10.1007\/s40265-012-0003-1","journal-title":"Drugs"},{"key":"5454_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250647","author":"A Nachankar","year":"2022","unstructured":"Nachankar A, Katyal A, Bansal N, Bishnoi A (2022) Hungry bone syndrome like presentation following single-dose Denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2022-250647","journal-title":"BMJ Case Rep"},{"key":"5454_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.joms.2015.11.004","volume":"74","author":"Y Nariai","year":"2016","unstructured":"Nariai Y, Kanno T, Sekine J (2016) Histopathological features of secondary squamous cell carcinoma around a dental implant in the mandible after chemoradiotherapy: a case report with a clinicopathological review. J Oral Maxillofac Surg 74:982\u2013990. https:\/\/doi.org\/10.1016\/j.joms.2015.11.004","journal-title":"J Oral Maxillofac Surg"},{"key":"5454_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly Ibandronate in men with low bone density. Bone 46:970\u2013976. https:\/\/doi.org\/10.1016\/j.bone.2009.12.034","journal-title":"Bone"},{"key":"5454_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/cc13897","volume":"18","author":"N Petejova","year":"2014","unstructured":"Petejova N, Martinek A (2014) Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 18:224. https:\/\/doi.org\/10.1186\/cc13897","journal-title":"Crit Care"},{"key":"5454_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.beem.2014.09.003","volume":"28","author":"JY Reginster","year":"2014","unstructured":"Reginster JY, Neuprez A, Dardenne N, Beaudart C, Emonts P, Bruyere O (2014) Efficacy and safety of currently marketed anti-osteoporosis medications. Best Pract Res Clin Endocrinol Metab 28:809\u2013834. https:\/\/doi.org\/10.1016\/j.beem.2014.09.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"5454_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q (2022) Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health 10:996179. https:\/\/doi.org\/10.3389\/fpubh.2022.996179","journal-title":"Front Public Health"},{"key":"5454_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169735","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu Y, Chen J, Ding Y, Zhang Q (2023) Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol 14:1169735. https:\/\/doi.org\/10.3389\/fimmu.2023.1169735","journal-title":"Front Immunol"},{"key":"5454_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.reuma.2012.06.007","volume":"9","author":"L Silva-Fernandez","year":"2013","unstructured":"Silva-Fernandez L, Rosario MP, Martinez-Lopez JA, Carmona L, Loza E (2013) Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin 9:42\u201352. https:\/\/doi.org\/10.1016\/j.reuma.2012.06.007","journal-title":"Reumatol Clin"},{"key":"5454_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(11)61226-9","journal-title":"Lancet"},{"key":"5454_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/imj.13001","volume":"46","author":"B Smyth","year":"2016","unstructured":"Smyth B, Ong S (2016) Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. J Intern Med 46:360\u2013363. https:\/\/doi.org\/10.1111\/imj.13001","journal-title":"J Intern Med"},{"key":"5454_CR37","doi-asserted-by":"publisher","unstructured":"Tan WN, Rossi A, Haroun KB, Conner GR, McKinnon B, Ranasinghe V, Shabani S, Coblens OM (2024) Denosumab-induced maxillary osteonecrosis: a case study on long-term complications in multiple myeloma treatment. Ent-Ear Nose Throat J 1455613241263181. https:\/\/doi.org\/10.1177\/01455613241263181","DOI":"10.1177\/01455613241263181"},{"key":"5454_CR38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1600-0625.2011.01303.x","volume":"20","author":"F Toberer","year":"2011","unstructured":"Toberer F, Sykora J, Gottel D, Ruland V, Hartschuh W, Enk A, Luger TA, Beissert S, Loser K, Joos S, Krammer PH, Kuhn A (2011) Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol 20:600\u2013602. https:\/\/doi.org\/10.1111\/j.1600-0625.2011.01303.x","journal-title":"Exp Dermatol"},{"key":"5454_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413640","author":"F Vescini","year":"2021","unstructured":"Vescini F, Chiodini I, Falchetti A, Palermo A, Salcuni AS, Bonadonna S, De Geronimo V, Cesareo R, Giovanelli L, Brigo M, Bertoldo F, Scillitani A, Gennari L (2021) Management of osteoporosis in men: a narrative review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222413640","journal-title":"Int J Mol Sci"},{"key":"5454_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","volume":"10","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Eastell R, Schini M (2022) Osteoporosis in men. Lancet Diabetes Endocrinol 10:273\u2013283. https:\/\/doi.org\/10.1016\/S2213-8587(22)00012-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5454_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","volume":"45","author":"L Wei","year":"2023","unstructured":"Wei L, Tian Y, Chen X, Guo X, Chen C, Zheng Y, Xu J, Ye X (2023) Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database. Int J Clin Pharm 45:622\u2013629. https:\/\/doi.org\/10.1007\/s11096-022-01514-4","journal-title":"Int J Clin Pharm"},{"key":"5454_CR42","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/14740338.2024.2322712","volume":"23","author":"X Xiong","year":"2024","unstructured":"Xiong X, Zhang X, Li X, Huang T (2024) Adverse events associated with brolucizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf 23:1447\u20131452. https:\/\/doi.org\/10.1080\/14740338.2024.2322712","journal-title":"Expert Opin Drug Saf"},{"key":"5454_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, Chen J, Zhao R, Wu Z, Wang L, Chen Z, Chen H, Lan Y (2024) Adverse drug events associated with linezolid administration: A real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol 15:1338902. https:\/\/doi.org\/10.3389\/fphar.2024.1338902","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05454-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:23:53Z","timestamp":1787621033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05454-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5454"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05454-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and the institutional requirements.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.","order":3,"name":"Ethics","label":"Publisher\u2019s note","group":{"name":"EthicsHeading","label":"Declarations"}}]}}